Eine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen Behandlungslinien neu zu definieren
BEERSE, Belgien, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, ein weltweit führendes Unternehmen im Bereich des multiplen Myeloms, gab heute neue Daten aus der Phase III-Studie MajesTEC-3 bekannt, die eine anhaltende Krankheitskontrolle und Überlebenszeit unter TECVAYLI ® (teclistamab) in Kombination mit darat…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Jenny McCarthy Begins Therapeutic Plasma Exchange Journey to Address Mold Toxicity and Environmental Toxins
- Dairy Council of California Launches New Explore Nutrition Educational Product to Help Upper Elementary Students Discover Food, Health and Agriculture
- Internet Society Launches Global Online Trust and Safety Hub as Part of Its Safer Internet Initiative
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →